Drug intelligence / Profile preview

AQR-008

Development stage: Preclinical
Lead developer: Aqur Biosciences
Modality: Peptides
Administration: Oral

Overview

AQR-008 is a therapeutic peptide developed by Aqur Biosciences for the treatment of hypercholesterolemia, including familial hypercholesterolemia and elevated LDL-C levels. The drug specifically targets the EGF-A domain of the Low-Density Lipoprotein Receptor (LDL-R). By binding to this domain, AQR-008 is designed to prevent the degradation of LDL-R, thereby increasing the receptor's availability on the cell surface to clear LDL cholesterol from the bloodstream. This mechanism mimics the effect of PCSK9 inhibitors by preserving LDL-R levels. AQR-008 is currently in preclinical development.

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on AQR-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AQR-008.

Explore the full profile